Compare DexCom, Inc. (DXCM) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares MSCI Indonesia ETF — how do they compare? DexCom, Inc. trades at $83.39 (market cap $31.86B), while iShares MSCI Indonesia ETF trades at $11.87 (market cap $409.22M). The key difference: DexCom, Inc. is far larger — about 77.9× iShares MSCI Indonesia ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares MSCI Indonesia ETF for 76 Days on average.
| DXCM | EIDO | |
|---|---|---|
Market Cap | $31.86B | $409.22M |
Volume | 3,607,070 | 879,527 |
Sector | Health | — |
52-Week High | $92.34 | $19.22 |
52-Week Low | $54.84 | $10.80 |
Typical Hold Time | 62 Days | 76 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
EIDO trades at $11.87, showing minimal daily movement with a 0.08% gain. Technical indicators signal a bearish trend, with moving averages and ADX pointing downward, though RSI levels hint at potential oversold conditions. Recent news highlights underperformance amid sector rotation away from Asian equities, with volume declining 21% below average. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to weak price action and bearish technicals. Risks include high financials exposure and slow EPS growth. Upside may depend on seasonal trends or valuation support, but current sentiment and institutional flows suggest continued pressure. Investors should weigh technical weakness against potential bargain opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
